Celltrion laid out a blueprint to accelerate strengthening its global new drug development capabilities based on open innovation.
The company held the Celltrion Science & Innovation Day 2026 (CSID) on the 26th at the Conrad Seoul in Yeouido and unveiled its next-generation new drug development strategy and plans to build a collaborative ecosystem. The event, held under the theme "Global new drugs opened by open innovation," was organized to inform the market of Celltrion's new drug development capabilities and vision and to convey its determination to leap forward as a global new drug corporations.
In particular, this year's event expanded the attendee pool beyond the existing domestic and overseas securities analysts to include institutional investors, venture capital (VC), and research institutions. Through this, the company said it raised the market's understanding of Celltrion's new drug pipeline and open innovation strategy.
On the day, Kwon Gi-seong, head of research and development at Celltrion, gave a presentation on "Celltrion's new drug vision," introducing next-generation antibody development strategies, technological differentiation, and commercialization directions. Celltrion emphasized that it is building a competitive new drug development model by combining its in-house research and development capabilities with innovative technologies from external partners.
Presentations by leaders of collaborating biotech corporations followed. Shin Min-jae, head of Kaizin, outlined a development strategy for autoimmune disease treatments, while Kim Maeng-seop, head of MustBio, introduced next-generation immuno-oncology technology. Lee Dae-seung, head of Portray, presented space biology-based technology, and Seok Cha-ok, head of Galux, gave a presentation on a new drug development platform using artificial intelligence (AI).
Jang So-yong, head of new business at Celltrion, introduced the open innovation roadmap and collaboration cases. Celltrion currently operates six open innovation programs with public institutions and universities nationwide and plans to expand the scope of collaboration to global markets, including the United States, Japan, and China.
Seo Jin-seok, head of Celltrion, who took the stage as the final presenter, said the company is pursuing new drug development across a range of therapeutic approaches, including antibody-drug conjugates (ADC), multispecific antibodies, new antibody-fusion proteins, peptides, and the microbiome. Seo added that the company will build success stories for global new drugs based on its capabilities across the full bio business lifecycle.
The market reaction was positive. Jeong Yi-su, an analyst at IBK Securities who attended the event, said, "We were able to confirm in detail the status and technological differentiation of the new drug pipeline that Celltrion is developing," adding, "It was an opportunity to deepen understanding of the value of the technologies and pipeline secured through open innovation."
Celltrion plans to run CSID, first held last year, as a regular event and continue sharing its research and development (R&D) capabilities and philosophy with the market.
Seo Jin-seok said, "Through this event, we conveyed more clearly to the market the competitiveness of Celltrion's new drug pipeline," adding, "We will continue to disclose new drug development results step by step and raise corporate value to leap forward as a global new drug corporations."